Menopur (Menotrophin)

Menotropin contains both follicle‑stimulating hormone (FSH) and luteinizing hormone (LH) activity. The hormones bind to their respective receptors on ovarian granulosa cells and testicular Leydig cells, activating adenylate cyclase and raising intracellular cAMP. This triggers follicle growth and estradiol production in women and testosterone synthesis that drives sperm production in men.

The dose of Menopur is individualized by the prescribing physician based on the patient’s hormonal profile, ovarian response, and treatment goals. Clinicians typically start with a low dose and adjust according to serial ultrasound and estradiol measurements, following established fertility clinic protocols.

Menopur is not intended for use during an established pregnancy and should be discontinued once pregnancy is confirmed. Safety data for breastfeeding are limited; therefore, the medication is generally avoided while nursing. Patients should discuss any concerns with their healthcare provider.

To order Menopur, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain handling) and any necessary import documentation.

The primary alternative to Menopur is recombinant FSH (e.g., follitropin alfa). Both provide FSH activity, but Menopur also contains LH activity, which can be advantageous for patients who need combined gonadotropin support. Recombinant products are highly purified and have a consistent batch‑to‑batch profile, while Menopur is derived from urinary sources and may be more cost‑effective in some markets.

Menopur must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and do not freeze or shake the solution. If a short‑term excursion above 8 °C occurs, the product should be used within 24 hours provided it remains visually clear and free of particles.

Menopur is supplied as a sterile injectable solution. After reconstitution according to the package insert, it is administered by a trained professional via intramuscular or subcutaneous injection. The injection site is typically the abdomen or thigh, and dosing intervals are determined by the treating physician based on monitoring results.

The most serious risks include severe ovarian hyperstimulation syndrome (OHSS), which can cause rapid weight gain, abdominal distension, and electrolyte imbalance, and thromboembolic events such as deep‑vein thrombosis. Rarely, anaphylactic reactions may occur. Patients should be educated to seek immediate medical attention if they experience severe abdominal pain, shortness of breath, or signs of an allergic reaction.

Menopur is contraindicated in women who are already pregnant, have uncontrolled thyroid disease, active ovarian cysts, or a known hypersensitivity to menotropin or any excipients. Men with severe pituitary disorders that are not correctable, or those with a history of thromboembolic disease, should also avoid using this medication unless specifically directed by a specialist.